SPTX

insider transactions

Seaport Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

+1.1M

1.1M buy · 0 sell

Net value · 365d

$19.8M

$19.8M in · $0 out

Sentiment · 365d

Net buying

100% buying · 0% selling

Open-market trades · 365d

1.1M buy · 0 sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Exercise·C
May 4, 26

Lauren White KEY

Chief Financial Officer

$0

21.1K sh

Own New
Exercise·C
May 4, 26

Lauren White KEY

Chief Financial Officer

—

6.7K sh

Own New
Exercise·C
May 4, 26

Denice Torres

Director

$0

42.1K sh

Own New
Exercise·C
May 4, 26

Denice Torres

Director

—

13.4K sh

Own New
Exercise·C
May 4, 26

Antony Loebel

Chief Medical Officer

$0

63.2K sh

Own New
Exercise·C
May 4, 26

Antony Loebel

Chief Medical Officer

—

20.1K sh

Own New
Exercise·C
May 4, 26

Lana Gladstein

General Counsel

$0

105.3K sh

Own New
Exercise·C
May 4, 26

Lana Gladstein

General Counsel

—

33.5K sh

Own New
Exercise·C
May 4, 26

Michael Cunyuan Chen

Chief Scientific Officer

$0

10.5K sh

Own New
Exercise·C
May 4, 26

Michael Cunyuan Chen

Chief Scientific Officer

—

3.4K sh

Own New
Exercise·C
May 4, 26

ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis

10% Owner

$0

2.7M sh

Own New
Exercise·C
May 4, 26

ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis

10% Owner

$0

2.5M sh

Own New
Buy·P
May 4, 26

ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis

10% Owner

$19.8M

1.1M sh · $18.00

Own +21%
Exercise·C
May 4, 26

ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis

10% Owner

—

2.7M sh

Own +107%
Exercise·C
May 4, 26

ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis

10% Owner

—

2.5M sh

Own New
Exercise·C
May 4, 26

PureTech Health plc / PureTech LYT, Inc.

10% Owner

$0

3.0M sh

Own New
Exercise·C
May 4, 26

PureTech Health plc / PureTech LYT, Inc.

10% Owner

$0

8.4M sh

Own New
Exercise·C
May 4, 26

PureTech Health plc / PureTech LYT, Inc.

10% Owner

$0

40.0M sh

Own New
Exercise·C
May 4, 26

PureTech Health plc / PureTech LYT, Inc.

10% Owner

—

965.3K sh

Own +6%
Exercise·C
May 4, 26

PureTech Health plc / PureTech LYT, Inc.

10% Owner

—

2.7M sh

Own +21%
Exercise·C
May 4, 26

PureTech Health plc / PureTech LYT, Inc.

10% Owner

—

12.7M sh

Own +4211%
Grant·A
Apr 30, 26

Daphne Zohar KEY

Chief Executive Officer

$0

1.5M sh

Own New
Grant·A
Apr 30, 26

Daphne Zohar KEY

Chief Executive Officer

$0

271.8K sh

Own New
Grant·A
Apr 30, 26

Lauren White KEY

Chief Financial Officer

$0

63.7K sh

Own New
Grant·A
Apr 30, 26

David E. Wheadon

Director

$0

12.3K sh

Own New
Grant·A
Apr 30, 26

Denice Torres

Director

$0

12.3K sh

Own New
Grant·A
Apr 30, 26

Sandra E Peterson

Director

$0

12.3K sh

Own New
Grant·A
Apr 30, 26

Sharon Mates

Director

$0

49.0K sh

Own New
Grant·A
Apr 30, 26

Antony Loebel

Chief Medical Officer

$0

63.7K sh

Own New
Grant·A
Apr 30, 26

Robert J. Hombach

Director

$0

12.3K sh

Own New
Grant·A
Apr 30, 26

Lana Gladstein

General Counsel

$0

63.7K sh

Own New
Grant·A
Apr 30, 26

Michael Cunyuan Chen

Chief Scientific Officer

$0

63.7K sh

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 4, 2026	Lauren White KEY	Chief Financial Officer	Exercise C	21.1K	New	—	$0
May 4, 2026	Lauren White KEY	Chief Financial Officer	Exercise C	6.7K	New	—	—
May 4, 2026	Denice Torres	Director	Exercise C	42.1K	New	—	$0
May 4, 2026	Denice Torres	Director	Exercise C	13.4K	New	—	—
May 4, 2026	Antony Loebel	Chief Medical Officer	Exercise C	63.2K	New	—	$0
May 4, 2026	Antony Loebel	Chief Medical Officer	Exercise C	20.1K	New	—	—
May 4, 2026	Lana Gladstein	General Counsel	Exercise C	105.3K	New	—	$0
May 4, 2026	Lana Gladstein	General Counsel	Exercise C	33.5K	New	—	—
May 4, 2026	Michael Cunyuan Chen	Chief Scientific Officer	Exercise C	10.5K	New	—	$0
May 4, 2026	Michael Cunyuan Chen	Chief Scientific Officer	Exercise C	3.4K	New	—	—
May 4, 2026	ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis	10% Owner	Exercise C	2.7M	New	—	$0
May 4, 2026	ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis	10% Owner	Exercise C	2.5M	New	—	$0
May 4, 2026	ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis	10% Owner	Buy P	1.1M	+21%	$18.00	$19.8M
May 4, 2026	ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis	10% Owner	Exercise C	2.7M	+107%	—	—
May 4, 2026	ARCH Venture Partners XII, LLC / ARCH Venture Partners XII, L.P. / ARCH Venture Fund XII, L.P. / Keith Crandell / Robert Nelsen / Kristina Burow / Steven Gillis	10% Owner	Exercise C	2.5M	New	—	—
May 4, 2026	PureTech Health plc / PureTech LYT, Inc.	10% Owner	Exercise C	3.0M	New	—	$0
May 4, 2026	PureTech Health plc / PureTech LYT, Inc.	10% Owner	Exercise C	8.4M	New	—	$0
May 4, 2026	PureTech Health plc / PureTech LYT, Inc.	10% Owner	Exercise C	40.0M	New	—	$0
May 4, 2026	PureTech Health plc / PureTech LYT, Inc.	10% Owner	Exercise C	965.3K	+6%	—	—
May 4, 2026	PureTech Health plc / PureTech LYT, Inc.	10% Owner	Exercise C	2.7M	+21%	—	—
May 4, 2026	PureTech Health plc / PureTech LYT, Inc.	10% Owner	Exercise C	12.7M	+4211%	—	—
Apr 30, 2026	Daphne Zohar KEY	Chief Executive Officer	Grant A	1.5M	New	—	$0
Apr 30, 2026	Daphne Zohar KEY	Chief Executive Officer	Grant A	271.8K	New	—	$0
Apr 30, 2026	Lauren White KEY	Chief Financial Officer	Grant A	63.7K	New	—	$0
Apr 30, 2026	David E. Wheadon	Director	Grant A	12.3K	New	—	$0
Apr 30, 2026	Denice Torres	Director	Grant A	12.3K	New	—	$0
Apr 30, 2026	Sandra E Peterson	Director	Grant A	12.3K	New	—	$0
Apr 30, 2026	Sharon Mates	Director	Grant A	49.0K	New	—	$0
Apr 30, 2026	Antony Loebel	Chief Medical Officer	Grant A	63.7K	New	—	$0
Apr 30, 2026	Robert J. Hombach	Director	Grant A	12.3K	New	—	$0
Apr 30, 2026	Lana Gladstein	General Counsel	Grant A	63.7K	New	—	$0
Apr 30, 2026	Michael Cunyuan Chen	Chief Scientific Officer	Grant A	63.7K	New	—	$0

About SPTX insider trading

This page tracks insider transactions for Seaport Therapeutics, Inc. (SPTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.